19 February 2025 - NICE has published final evidence-based recommendations on the use of selpercatinib (Retsevmo) for the treatment of ...
19 February 2025 - NICE has published final evidence-based recommendations on durvalumab (Imfinzi) with etoposide and either carboplatin or cisplatin ...
14 February 2025 - Health technology assessment is used extensively by the PBAC to inform medicine funding recommendations in Australia. ...
13 February 2025 - After nearly two years of stalled discussions, the Keytruda (pembrolizumab) reimbursement expansion debate has finally begun. ...
12 February 2025 - NICE has published final evidence-based recommendations on the use of olaparib (Lynparza) for the treatment of ...
12 February 2025 - We’ve partnered with the US based ICER and the Canadian Drug Agency (CDA-AMC) to establish the Health ...
12 February 2025 - NICE has published final evidence-based recommendations on the use of selpercatinib (Retsevmo) for the treatment of ...
12 February 2025 - NICE has published final evidence-based recommendations on the use of selpercatinib (Retsevmo) for the treatment of ...
12 February 2025 - NICE has published final evidence-based recommendations on the use of ganaxolone (Ztalmy) for the treatment of ...
7 February 2025 - Gilead's triple negative breast cancer treatment Trodelvy (trastuzumab govitecan) had surmounted a significant hurdle for health ...
10 February 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
6 February 2025 - Public comment period now open until 6 March 2025; requests to make oral comment during public ...
5 February 2025 - Current evidence suggests that suzetrigine may provide a net health benefit when compared to no systemic ...
10 February 2025 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice ...
26 July 2024 - Eisai and Biogen announced today that the CHMP of the EMA has adopted a negative opinion on ...